Edition:
United States

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

94.51USD
23 Oct 2017
Change (% chg)

-- (--)
Prev Close
$94.51
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,676,433
52-wk High
$98.20
52-wk Low
$55.10

Chart for

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Overall

Beta: 1.53
Market Cap(Mil.): $150,657.91
Shares Outstanding(Mil.): 1,594.09
Dividend: 0.64
Yield (%): 2.71

Financials

  Industry Sector
P/E (TTM): -- 31.57 16.30
EPS (TTM): -- -- --
ROI: -- 14.87 11.19
ROE: -- 16.12 15.02

BRIEF-Alector and AbbVie announce collaboration

* Alector and AbbVie announce collaboration to advance a novel class of immune therapies for patients with Alzheimer's disease

7:18am EDT

BRIEF-Cerveau Technologies signs agreement with AbbVie for Novel Tau imaging agent

* Cerveau Technologies Inc signs license and supply agreement with AbbVie for Novel Tau imaging agent

Oct 23 2017

BRIEF-Abbvie and harpoon therapeutics announce immuno-oncology research collaboration

* Abbvie and Harpoon Therapeutics announce immuno-oncology research collaboration

Oct 18 2017

AbbVie, Abbott duck Depakote off-label marketing case on appeal

A federal appeals court on Thursday upheld the dismissal of a class action lawsuit accusing AbbVie Inc and Abbott Laboratories of violating federal racketeering laws by promoting the drug Depakote for off-label uses.

Oct 12 2017

REFILE-UPDATE 1-US NIH, 11 drugmakers partner to accelerate cancer therapy research

Oct 12 The Trump Administration threw its support behind a public-private partnership with 11 drug companies to advance a new class of drugs that uses the body's immune system to fight cancer.

Oct 12 2017

BRIEF-AbbVie and Turnstone Biologics announce global collaboration on viral immunotherapies in oncology

* AbbVie and Turnstone Biologics announce global collaboration on viral immunotherapies in oncology

Oct 10 2017

Second U.S. jury finds AbbVie misrepresented risks of AndroGel

A U.S. jury on Thursday ordered AbbVie Inc to pay more than $140 million to a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack, the plaintiff's lawyer said in a statement.

Oct 05 2017

UPDATE 1-Second U.S. jury finds AbbVie misrepresented risks of AndroGel

Oct 5 A U.S. jury on Thursday ordered AbbVie Inc to pay more than $140 million to a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack, the plaintiff's lawyer said in a statement.

Oct 05 2017

AbbVie hit with $140 mln verdict in AndroGel trial -lawyer

Oct 5 A U.S. jury on Thursday ordered AbbVie Inc to pay more than $140 million to a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack, the plaintiff's lawyer said in an emailed statement.

Oct 05 2017

AbbVie, Amgen settlement sets Humira U.S. biosimilar launch for 2023

Amgen Inc has reached a settlement with AbbVie Inc that will delay the U.S. launch of Amgen's cheaper biosimilar version of AbbVie's cash cow, the blockbuster rheumatoid arthritis drug Humira, until Jan. 31, 2023, the companies said on Thursday.

Sep 28 2017

Competitors

Earnings vs. Estimates